244 related articles for article (PubMed ID: 29225163)
1. Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation.
Shultes KC; Arp C; Stockerl-Goldstein K; Trinkaus K; DeFrates S
Biol Blood Marrow Transplant; 2018 Apr; 24(4):687-693. PubMed ID: 29225163
[TBL] [Abstract][Full Text] [Related]
2. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK;
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
[TBL] [Abstract][Full Text] [Related]
4. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H
Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892
[TBL] [Abstract][Full Text] [Related]
5. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
7. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
8. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis.
Takahashi T; Jaber MM; Al-Kofahi M; Weisdorf D; Brunstein C; Bachanova V; Brundage RC; Jacobson PA; Kirstein MN
Transplant Cell Ther; 2022 Dec; 28(12):845.e1-845.e8. PubMed ID: 36167308
[TBL] [Abstract][Full Text] [Related]
10. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
14. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
16. Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience.
Samaras P; Blickenstorfer M; Haile SR; Siciliano RD; Petrausch U; Mischo A; Zweifel M; Honegger H; Schanz U; Stussi G; Taverna C; Bauer S; Knuth A; Stenner-Liewen F; Renner C
Swiss Med Wkly; 2011; 141():w13203. PubMed ID: 21630163
[TBL] [Abstract][Full Text] [Related]
17. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.
Lahuerta JJ; Martinez-Lopez J; Grande C; Bladé J; de la Serna J; Alegre A; García-Laraña J; Caballero D; Sureda A; de la Rubia J; Alvarez AM; Marín J; Escudero A; Conde E; Perez-Equiza K; García Ruiz JC; Moraleda JM; León A; Bargay J; Cabrera R; Hernandez-García MT; Diaz-Mediavilla J; Miguel JS
Br J Haematol; 2000 Apr; 109(1):138-47. PubMed ID: 10848793
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma.
Parmar SR; Bookout R; Shapiro JF; Tombleson R; Perkins J; Kim J; Yue B; Tomblyn M; Alsina M; Nishihori T
Bone Marrow Transplant; 2014 Jun; 49(6):761-6. PubMed ID: 24662419
[TBL] [Abstract][Full Text] [Related]
19. Impact of melphalan day -1 vs day -2 on outcomes after autologous stem cell transplant for multiple myeloma.
Merino A; Shanley R; Rashid F; Langer J; Dolan M; Tu S; Jurdi NE; Rogosheske J; Hanna K; DeFor T; Janakiram M; Weisdorf D
Front Immunol; 2024; 15():1310752. PubMed ID: 38504993
[TBL] [Abstract][Full Text] [Related]
20. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
